Prescription drug · NDA
Ionosol MB and Dextrose NDC 0990-7372
Dextrose monohydrate 5 g/100mL + 5 more ingredients · Injection, Solution · Intravenous · ICU Medical Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0990-7372-03 | 00990737203 | 24 POUCH in 1 CASE (0990-7372-03) / 1 BAG in 1 POUCH / 500 mL in 1 BAGMarketed from Jan 1, 2020 | |
| 0990-7372-62 | 00990737262 | 24 POUCH in 1 CASE (0990-7372-62) / 1 BAG in 1 POUCH / 250 mL in 1 BAGMarketed from Jul 1, 2019 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ionosol MB and Dextrose
- Generic name (nonproprietary)
- dextrose monohydrate, sodium lactate, potassium chloride, magnesium chloride, potassium phosphate, monobasic, and sodium phosphate, monobasic, monohydrate
- Active ingredients
- Dextrose monohydrate — 5 g/100mLSodium lactate — 260 mg/100mLPotassium chloride — 141 mg/100mLMagnesium chloride — 30 mg/100mLMonobasic potassium phosphate — 15 mg/100mLSodium phosphate, Monobasic, Monohydrate — 25 mg/100mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- ICU Medical Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 019513
- Marketing start
- Listing expires
- Other FDA classes
- Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Increased Large Intestinal Motility (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Inhibition Small Intestine Fluid/Electrolyte Absorption (Physiologic effect)Magnesium Ion Exchange Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Osmotic Activity (Mechanism)Potassium Compounds (Chemical structure)Potassium Compounds (Chemical structure)Stimulation Large Intestine Fluid/Electrolyte Secretion (Physiologic effect)
- Identifiers
- Product ID 0990-7372_f6e10cf9-7244-440c-88a3-a100a51bb74cSPL ID f6e10cf9-7244-440c-88a3-a100a51bb74cSPL set ID 1b457b1d-0e80-4578-ba6f-dedf513fc962RxCUI 800644, 800648UNII LX22YL083G, TU7HW0W0QT, 660YQ98I10, 02F3473H9O, 4J9FJ0HL51, 593YOG76RN
- Pharmacologic class
- Calculi Dissolution Agent; Osmotic Laxative; Potassium Salt
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400990737203followed by a unit qualifier and the quantityPackage 00990-7372-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves.
Excerpt only. Read the full label for complete information.